When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AUPH - Kezar Life Sciences: Targeting The Immunoproteasome To Treat Autoimmunity
Aurinia Pharmaceuticals Inc
Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines.
The company's lead asset, KZR-616, is a first-in-class inhibitor of the immunoproteasome with the potential to become a pipeline-in-a-pill for autoimmunity.
Kezar has the cash to complete two phase 2 trials set for completion in 2021 creating upcoming catalysts for the stock.